Login / Signup

O -GalNAc glycosylation affects the immunogenicity of the receptor-binding domain (RBD) of SARS-CoV-2 spike protein.

Yongheng RongXingyun WangWeian MaoMin ChenShengjun WangPeng George WangYunjiao HeYun Kong
Published in: Chemical communications (Cambridge, England) (2023)
The spike protein of SARS-CoV-2 has been widely used as an effective vaccine immunogen, although some limitations still remain. Herein, O -GalNAc glycosylated RBD (Tn-RBD) was synthesized as an antigen via in vitro glycosylation reactions. The inhibition ability against hACE2 binding of antibodies induced with Tn-RBD was 30-40% increased compared to that induced with RBD. This result implies that Tn-glycosylation might play important roles in the immunogenicity of the RBD protein, which should be considered in the design of novel vaccines to fight against COVID-19.
Keyphrases
  • sars cov
  • binding protein
  • respiratory syndrome coronavirus
  • high glucose
  • diabetic rats
  • coronavirus disease
  • protein protein
  • amino acid
  • oxidative stress
  • drug induced
  • endothelial cells
  • transcription factor